In Vivo Activity of Diphenylantimony(III) and Diorganotin(IV) Derivatives Against P388 Leukemia
Author Information
Author(s): Bernhard K. Keppler, Cristian Silvestru, Ionel Haiduc
Primary Institution: Anorganisch-Chemisches Institut der Universität Heidelberg
Hypothesis
The study investigates the antitumor activity of organometallic compounds against P388 leukemia in mice.
Conclusion
Some organometallic compounds increased the lifespan of mice with leukemia by more than 20%, with the best results from a specific diphenylantimony compound.
Supporting Evidence
- All tested compounds showed marginal activity against P388 leukemia.
- The best compound increased the lifespan of treated mice by 36%.
- Some compounds were more active than others in increasing survival rates.
Takeaway
Scientists tested some special chemicals to see if they could help mice with leukemia live longer, and one of them worked really well.
Methodology
Mice with P388 leukemia were treated with various organometallic compounds and their survival was monitored.
Limitations
The compounds showed only marginal activity and increasing doses led to stronger toxic effects.
Participant Demographics
DBA/2 and BDF1 female mice, weighing 20-22 g.
Want to read the original?
Access the complete publication on the publisher's website